Why the study?
Does TGF-beta antagonism prevent diabetic vascular disease in patients with IDDM and albuminuria?
Does TGF-beta antagonism prevent diabetic vascular disease in patients with IDDM and albuminuria?
This hypothesis paper proposes that TGF-beta overproduction drives both micro- and macrovascular complications in diabetes, suggesting TGF-beta antagonists as potential future therapies.
Answers are grounded in this paper and cite their sources.
TGF-beta antagonism remains untested clinically in diabetic vascular disease; leaves open a unifying therapeutic target pending prospective trials.
Patients with insulin-dependent diabetes mellitus (IDDM) and albuminuria are at high risk for severe micro- and macrovascular complications. Diabetic vascular complications are characterized by structural alterations of extracellular matrix (ECM) components in glomeruli and large vessel walls, namely, accumulation of collagen IV, collagen VI and fibronectin and relative decrease of heparan sulphate proteoglycan (HSPG). We hypothesize that the defect remodelling of ECM contributing to nephropathy and macrovascular disease is induced by overproduction of transforming growth factor-beta (TGF-beta). Recent reports indicate that hyperglycaemia, increased intraglomerular pressure, and glycated proteins potentially induce overproduction of TGF-beta in diabetes. TGF-beta stimulates production of ECM components such as collagen IV, fibronectin, proteoglycans (decorin and biglycan) without increasing HSPG. TGF-beta overproduction leads to glomerulosclerosis and TGF-beta is a causal factor in myointimal hyperplasia after balloon injury of carotid artery. It mediates angiotensin II modulator effect on smooth muscle cell growth. These findings may indicate TGF-beta overproduction to be a common pathogenetic step explaining the well-known association between micro- and macrovascular complications in diabetic patients. TGF-beta antagonists, such as decorin, betaglycan, and possibly also heparin, might be potential candidates for future therapy to prevent diabetic vascular disease.
No takes yet. Share an insight, caveat, or question.
Yokoyama et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: